Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease
详细信息 查看全文
- 作者：Pia Runeberg-Roosa ; pia.runeberg@helsinki.fi" class="auth_mail" title="E-mail the corresponding author ; Elisa Piccininia ; 1 ; Anna-Maija Penttinena ; 1 ; Kert Mä ; tlika ; Hanna Heikkinena ; Satu Kuurea ; 2 ; Maxim M. Bespalova ; 3 ; Johan Perä ; nena ; 4 ; Enrique Garea-Rodrí ; guezb ; 5 ; Eberhard Fuchsc ; Mikko Airavaaraa ; Nisse Kalkkinena ; Richard Pennd ; 6 ; Mart Saarmaa
- 关键词：GDNF ; Glial cell line-Derived Neurotrophic Factor ; IHC ; immunohistochemical ; GAPDH ; glyceraldehyde 3-phosphate dehydrogenase ; GFRα1 ; GDNF family receptor α1 ; GFRα2 ; GDNF family receptor α2 ; IP ; immunoprecipitated ; MPTP ; 1-methyl-4-phenyl-1 ; 2 ; 3 ; 6-tetrahydropyridine ; NRTN ; neurturin ; NV1&ndash ; 4 ; V5-tagged NRTN variants N1-4 ; N1&ndash ; 4 ; untagged NRTN variants ; OHDA ; hydroxydopamine ; PD ; Parkinson's disease ; pgsA 745 cells ; CHO cells deficient in heparan sulfate from ATCC ; P-TYR ; phosphotyrosine
- 刊名：Neurobiology of Disease
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：96
- 期：Complete
- 页码：335-345
- 全文大小：1552 K
文摘
- •
We developed new NRTN variants for treatment of PD.
- •
10">All new NRTN variants are biologically active.
- •
15">Within the brain two of the new NRTN variants diffuse better than WT NRTN.
- •
These two new NRTN variants are also more stable than WT NRTN.
- •
One of the new NRTN variants is more efficient than GDNF in a rodent model of PD.